About mersana therapeutics inc. - MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
MRSN At a Glance
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, Massachusetts 02139
| Phone | 1-617-498-0020 | Revenue | 40.50M | |
| Industry | Biotechnology | Net Income | -69,192,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 9.882% | |
| Fiscal Year-end | 12 / 2025 | Employees | 102 | |
| View SEC Filings |
MRSN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.327 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.966 |
| Enterprise Value to Sales | 1.71 |
| Total Debt to Enterprise Value | 0.414 |
MRSN Efficiency
| Revenue/Employee | 397,029.412 |
| Income Per Employee | -678,352.941 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.218 |
MRSN Liquidity
| Current Ratio | 2.192 |
| Quick Ratio | 2.192 |
| Cash Ratio | 2.155 |
MRSN Profitability
| Gross Margin | 95.98 |
| Operating Margin | -181.09 |
| Pretax Margin | -169.825 |
| Net Margin | -170.857 |
| Return on Assets | -37.328 |
| Return on Equity | -505.143 |
| Return on Total Capital | -361.448 |
| Return on Invested Capital | -203.518 |
MRSN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 149.674 |
| Total Debt to Total Assets | 19.806 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 63.992 |